Author details

Full Name

Sameer Agnihotri

Affiliation

ORCID

Career Start Year

2009

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37798921	Characterization of low-grade epilepsy-associated tumor from implanted stereoelectroencephalography electrodes.	Epilepsia Open	2024
36849558	A neurodevelopmental epigenetic programme mediated by SMARCD3-DAB1-Reelin signalling is hijacked to promote medulloblastoma metastasis.	Nat Cell Biol	2023
36115566	Major Genetic Motifs in Pituitary Adenomas: A Practical Literature Update.	World Neurosurgery	2023
37944590	Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.	Nat Med	2023
37737247	Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas.		2023
37152806	Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeutics.		2023
37014128	Targeting mitochondrial energetics reverses panobinostat- and marizomib-induced resistance in pediatric and adult high-grade gliomas.	Mol Oncol	2023
37439870	Dual Role of CXCL8 in Maintaining the Mesenchymal State of Glioblastoma Stem Cells and M2-Like Tumor-Associated Macrophages.	Clin Cancer Res	2023
36934350	Sterol regulatory element-binding protein 2 maintains glioblastoma stem cells by keeping the balance between cholesterol biosynthesis and uptake.	Neuro Oncol	2023
36993741	Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.	Res Sq	2023
37432626	Radiation-Induced Meningiomas.	Adv Exp Med Biol	2023
36795488	Sorting nexin 10 sustains PDGF receptor signaling in glioblastoma stem cells via endosomal protein sorting.	JCI Insight	2023
37426447	Immuno-PET Imaging of CD69 Visualizes T-Cell Activation and Predicts Survival Following Immunotherapy in Murine Glioblastoma.	Cancer Res Commun	2023
34753803	MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer.	Molecular Cancer Research	2022
35659339	PDGF signaling inhibits mitophagy in glioblastoma stem cells through N<sup>6</sup>-methyladenosine.	Dev Cell	2022
36043990	Hurdling over the blood-brain barrier with exosome technology.	Neuro-Oncology	2022
35841593	Î²2-Microglobulin Maintains Glioblastoma Stem Cells and Induces M2-like Polarization of Tumor-Associated Macrophages.	Cancer Res	2022
35710946	Brain cancer stem cells: resilience through adaptive plasticity and hierarchical heterogeneity.	Nat Rev Cancer	2022
36305736	BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.	Cancer Discov	2022
35383171	Integrative analysis of non-small cell lung cancer patient-derived xenografts identifies distinct proteotypes associated with patient outcomes.	Nat Commun	2022
36338734	Circulating tumor DNA - A potential aid in the management of chordomas.	Frontiers in Oncology	2022
35739422	Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.	Nat Cancer	2022
35422502	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome.	Nat Cancer	2022
36471067	The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location.	Nat Genet	2022
36524349	Correction: PINK1 Is a Negative Regulator of Growth and the Warburg Effect in Glioblastoma.	Cancer Res	2022
34058053	Reversing tozasertib resistance in glioma through inhibition of pyruvate dehydrogenase kinases.	Mol Oncol	2022
35047821	The dominant TP53 hotspot mutation in -mutant astrocytoma, R273C, has distinctive pathologic features and sex-specific prognostic implications.	Neuro-Oncology Advances	2022
35121939	A vaccine for glioma.	Nat Cancer	2021
34175981	Impact of acute lymphoblastic leukemia induction therapy: findings from metabolomics on non-fasted plasma samples from a biorepository.	Metabolomics	2021
33963192	Loss of function mutations in GEMIN5 cause a neurodevelopmental disorder.	Nat Commun	2021
33741710	ZFTA-RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma.	Cancer Discov	2021
34228644	Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma.	J Clin Invest	2021
34007966	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment.	Neurooncol Adv	2021
33713404	Not all mouse blood-brain barriers are created equal.	Neuro-Oncology	2021
34025646	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.	Front Immunol	2021
33025139	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.	Acta Neuropathol	2021
33112994	Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.	Acta Neuropathol	2021
33277484	Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer.	Nat Commun	2020
32238439	Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma Resistance.	Mol Cancer Res	2020
32445698	Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.	Cell	2020
32817015	Anarchy or Respect the Hierarchy? The Complexity of Glioblastoma.	Cancer Research	2020
31391321	Targeting pyrimidine synthesis accentuates molecular therapy response in glioblastoma stem cells.	Sci Transl Med	2019
30322879	Ketoconazole and Posaconazole Selectively Target HK2-expressing Glioblastoma Cells.	Clin Cancer Res	2019
31526762	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.	Cancer Cell	2019
31085178	Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.	Cancer Cell	2019
30737375	CIC protein instability contributes to tumorigenesis in glioblastoma.	Nat Commun	2019
31201162	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.	Cancer Res	2019
30835699	Childhood brain tumors: current management, biological insights, and future directions.	J Neurosurg Pediatr	2019
31298284	Clinical Utility of GlioSeq Next-Generation Sequencing Test in Pediatric and Young Adult Patients With Brain Tumors.	J Neuropathol Exp Neurol	2019
29428974	Malignant rhabdoid tumors originating within and outside the central nervous system are clinically and molecularly heterogeneous.	Acta Neuropathol	2018